N-Acetyl Selank Amidate

GABAergic Gene Expression

Transcriptomic analysis has demonstrated Selank upregulates genes involved in GABAergic neurotransmission — including receptor subunits and downstream signaling components. This molecular work provides the foundation for how an anxiolytic can work without causing sedation.⁴

BDNF and Neuroplasticity

In murine hippocampal and frontal cortex tissue, Selank administration has been associated with increased BDNF mRNA and protein levels — changes linked to synaptic plasticity and the brain's capacity to adapt.

Generalized Anxiety Disorder

In clinical studies, Selank reduced anxiety scores comparably to benzodiazepine treatment — without sedation, cognitive impairment, or withdrawal. Comparative trials against phenazepam confirmed equivalent effect with substantially better tolerability.¹²

SSRI Augmentation

About 40% of patients starting antidepressants experience delayed onset or residual symptoms. When Selank was added during early treatment, 70% showed meaningful anxiety reduction by day 14 — improvements that persisted two weeks after stopping Selank.

Benzodiazepine Optimization

A 70-patient study demonstrated that Selank + phenazepam combination allowed benzodiazepine dose reduction with maintained efficacy — suggesting potential as an adjunct for benzodiazepine tapering protocols.⁵

Post-Viral Recovery

A 2024 randomized trial in 64 post-COVID patients found that adding intranasal Selank to standard care improved mental work capacity, reduced anxiety and depressive symptoms, and resolved fatigue better than standard care alone.

Clinical evidence comes primarily from Russian institutions with limited Western replication. Most studies run 2–4 weeks. Long-term safety has not been established.

The N-acetyl amidate modification enhances stability but creates a compound not identical to the Selank in clinical trials — pharmacokinetic equivalence should not be assumed.

1. Zozulya AA et al. "Efficacy of Selank in generalized anxiety disorders and neurasthenia." Neurosci Behav Physiol. 2008. PubMed
2. Medvedev VE et al. "Comparison of Selank and phenazepam in anxiety disorders." Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PubMed
3. Uchakina ON et al. "Immunomodulatory effects of Selank in anxiety-asthenic disorders." Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PubMed
4. Seredenin SB et al. "Selank affects expression of genes involved in GABAergic neurotransmission." Front Pharmacol. 2016. PMC
5. Medvedev VE et al. "Optimization of treatment of anxiety disorders with Selank." Zh Nevrol Psikhiatr Im S S Korsakova. 2015. PubMed

For laboratory research use only.